

## **Natco Pharma Limited**

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

June 8, 2018

Corporate Relationship Department

M/s. BSE Ltd Dalal Street, Fort Mumbai- 400 001 Manager - Listing

M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra — Kurla Complex

Bandra (E) Mumbai -400 051

Scrip Code: **524816** 

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

M Adinarayana

Company Secretary &

MAnderayann

Vice President (Legal & Corp Affairs)



## **Natco Pharma Limited**

Regd. Off: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243

Ref: PR/ 3 /2018-2019

**Press Release** 

Hyderabad, India, June 8th, 2018

## NATCO launches generic Posaconazole Injection- 1st time available in INDIA

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has launched a generic version of Posaconazole Injection, 300 mg/16.7ml, under its brand POSANAT. This is the first time an injection version of this drug available in India. POSANAT will be available in 18.0 mg/ml strength, a formulation for intravenous (IV) use. Posaconazole Injection is sold in the USA market by Merck under its brand name of NOXAFIL®.

Posaconazole injection is an antifungal agent & used in patients who are at high risk of developing infections due to being severely immunocompromised, such as associated with stem cell transplant or from chemotherapy.

For NATCO Pharma Limited

M Adinarayana Company Secretary &

Vice President (Legal & Corp Affairs)